40 GSK Annual Report 2018 Group financial review Reporting framework Costs for all other ordinary course smaller scale restructuring and Total and Adjusted results legal charges and expenses are retained within both Total and The Group financial review discusses the operating and financial Adjusted results.
performance of the Group, its cash flows and financial position and As Adjusted results include the benefits of Major restructuring our resources.
The results for each year are compared primarily with programmes but exclude significant costs such as significant the results of the preceding year.
legal, major restructuring and transaction items, they should not be regarded as a complete picture of the Groups financial performance, Total results which is presented in its Total results.
The exclusion of other Total reported results represent the Groups overall performance.
Adjusting items may result in Adjusted earnings being materially GSK also uses a number of adjusted, non-IFRS, measures to report higher or lower than Total earnings.
In particular, when significant the performance of its business.
Adjusted results and other nonimpairments, restructuring charges and legal costs are excluded, IFRS measures may be considered in addition to, but not as a Adjusted earnings will be higher than Total earnings.
substitute for or superior to, information presented in accordance GSK has undertaken a number of Major restructuring programmes with IFRS.
Adjusted results are defined below and other non-IFRS in recent years in response to significant changes in the Groups measures are defined on page 42. trading environment or overall strategy, or following material GSK believes that Adjusted results, when considered together with acquisitions, including the Novartis transaction in 2015.
Costs, Total results, provide investors, analysts and other stakeholders with both cash and non-cash, of these programmes are provided for helpful complementary information to understand better the financial as individual elements are approved and meet the accounting performance and position of the Group from period to period, and recognition criteria.
As a result, charges may be incurred over a allow the Groups performance to be more easily compared against number of years following the initiation of a Major restructuring the majority of its peer companies.
These measures are also used by programme.
management for planning and reporting purposes.
They may not be From time to time, the Group divests non-core investments, products directly comparable with similarly described measures used by other and businesses and records the profit or loss on disposal as an companies.
The most notable divestment in the past five years GSK encourages investors and analysts not to rely on any single was the disposal of the Oncology business as one element of the financial measure but to review GSKs Annual Reports, including three-part transaction with Novartis in 2015. the financial statements and notes, in their entirety.
Significant legal charges and expenses are those arising from the GSK is committed to continuously improving its financial reporting, settlement of litigation or government investigations that are not in in line with evolving regulatory requirements and best practice and the normal course and materially larger than more regularly occurring has made a number of changes in recent years.
In line with this individual matters.
They also include certain major legacy matters.
practice, GSK expects in 2019 to continue to review its reporting Reconciliations between Total and Adjusted results, providing further framework including, where relevant, the use of alternative information on the key Adjusting items for 2017 and 2018 are set out performance measures.
on page 51 and for the five years to 2018 are set out on pages 232 Adjusted results to 234.
Adjusted results exclude the following items from Total results, GSK provides earnings guidance to the investor community on together with the tax effects of all of these items: the basis of Adjusted results.
This is in line with peer companies amortisation of intangible assets excluding computer software and expectations of the investor community, supporting easier and goodwill comparison of the Groups performance with its peers.
GSK is not able to give guidance for Total results as it cannot reliably forecast impairment of intangible assets excluding computer software certain material elements of the Total results, particularly the future and goodwill fair value movements on contingent consideration and put options major restructuring costs, which include impairments of tangible that can and have given rise to significant adjustments driven by assets and computer software, under specific Board approved external factors such as currency and other movements in capital programmes that are structural, of a significant scale and where markets.
the costs of individual or related projects exceed 25 million, including integration costs following material acquisitions transaction-related accounting or other adjustments related to significant acquisitions proceeds and costs of disposals of associates, products and businesses: significant legal charges net of insurance recoveries and expenses on the settlement of litigation and government investigations: other operating income other than royalty income, and other items the impact of the enactment of the US Tax Cuts and Jobs Act in 2017.
41 GSK Annual Report 2018 Strategic report Governance and remuneration Financial statements Investor information Reporting framework continued Historical record of Adjusting items The reconcilations between Total and Adjusted operating profit over the last five years can be summarised as follows: 2018 2017 2016 2015 2014 m m m m m Total operating profit 5,483 4,087 2,598 10,322 3,597 Intangible asset amortisation 580 591 588 563 575 Intangible asset impairment 116 688 20 206 150 Major restructuring 809 1,056 970 1,891 750 Transaction-related items 1,977 1,599 3,919 2,238 839 Divestments, significant legal and other items 220 119 424 9,561 545 US tax reform 666 Adjusted operating profit 8,745 8,568 7,671 5,659 6,456 The analysis of the impact of transaction-related items on operating profit for each of the last five years is as follows: 2018 2017 2016 2015 2014 m m m m m Novartis Consumer Healthcare Joint Venture put option 658 986 1,133 83 Contingent consideration on former Shionogi-ViiV Healthcare JV including Shionogi preferential dividends 1,188 556 2,162 1,874 768 ViiV Healthcare put options and Pfizer preferential dividends 58 126 577 Contingent consideration on former Novartis Vaccines business 58 101 69 108 Other adjustments 131 82 22 173 71 Transaction-related items 1,977 1,599 3,919 2,238 839 Full reconciliations between Total and Adjusted results for 20142018 are set out on pages 232 to 234.
Further explanations on the Adjusting items for 2018 are reported on page 51.
Acquisition-related arrangements Non-controlling interests in ViiV Healthcare As consideration for the acquisition of Shionogis interest in the former Shionogi-ViiV Healthcare joint venture in 2012, Shionogi Trading profit allocations received the 10% equity stake in ViiV Healthcare and ViiV Healthcare Because ViiV Healthcare is a subsidiary of the Group, 100% of also agreed to pay additional future cash consideration to Shionogi, its operating results turnover, operating profit, profit after tax are contingent on the future sales performance of the products being included within the Group income statement and then a portion developed by that joint venture, principally dolutegravir.
Under of the earnings is allocated to the non-controlling interests owned IFRS 3 Business combinations, GSK was required to provide for by the other shareholders, in line with their respective equity the estimated fair value of this contingent consideration at the time shareholdings Pfizer 11.7% and Shionogi 10%.
Each of the of acquisition and is required to update the liability to the latest shareholders, including GSK, is also entitled to preferential dividends estimate of fair value at each subsequent period end.
The liability for determined by the performance of certain products that each the contingent consideration recognised in the balance sheet at the shareholder contributed.
As the relative performance of these date of acquisition was 659 million.
Subsequent re-measurements products changes over time, the proportion of the overall earnings are reflected within other operating income expense and within of ViiV Healthcare allocated to each shareholder will change.
In Adjusting items in the income statement in each period, and at particular, the increasing sales of  products 31 December 2018, the liability, which is discounted at 8.5%, have a favourable impact on the proportion of the preferential stood at 5,937 million, on a post-tax basis.
dividends that is allocated to GSK.
Adjusting items are allocated to shareholders based on their equity interests.
GSK was entitled to Cash payments to settle the contingent consideration are made approximately 85% of the Total earnings and 82% of the Adjusted to Shionogi by ViiV Healthcare each quarter, based on the actual earnings of ViiV Healthcare for 2018.
Re-measurements of the sales performance of the relevant products in the previous quarter.
liabilities for the preferential dividends allocated to Pfizer and These payments reduce the balance sheet liability and hence are Shionogi are included within other operating income.
not recorded in the income statement.
The cash payments made to Shionogi by ViiV Healthcare in 2018 were 793 million.
Because the liability is required to be recorded at the fair value of estimated future payments, there is a significant timing difference between the charges that are recorded in the Total income statement to reflect movements in the fair value of the liability and the actual cash payments made to settle the liability.
42 GSK Annual Report 2018 Group financial review continued Reporting framework continued The cash payments are reflected in the cash flow statement partly However, during Q1 2016, GSK notified Shionogi that it had in operating cash flows and partly within investing activities.
The tax irrevocably given up this right and accordingly recognised the liability relief on these payments is reflected in the Groups Adjusting items for the put option on the Groups balance sheet during Q1 2016 at as part of the tax charge.
The part of each payment relating to the an initial value of 926 million.
In Q4 2016, Shionogi irrevocably original estimate of the fair value of the contingent consideration on agreed to waive its put option and as a result GSK fide-recognised the acquisition of the Shionogi-ViiV Healthcare joint venture in 2012 the liability for this put option on the Groups balance sheet directly of 659 million is reported within investing activities in the cash flow to equity.
The value of the liability was 1,244 million when it was statement and the part of each payment relating to the increase in the fide-recognised.
liability since the acquisition is reported within operating cash flows.
GSK also has a call option over Shionogis shareholding in ViiV Movements in contingent consideration payable to Shionogi were Healthcare, which under the original agreements was exercisable in as follows: six month windows commencing in 2027, 2030 and 2032.
GSK has 2018 2017 now irrevocably agreed to waive the first two exercise windows, but m m the last six month window in 2032 remains.
As this call option is at Contingent consideration at beginning of the year 5,542 5,304 fair value, it has no value for accounting purposes.
Re-measurement through income statement 1,188 909 Free cash flow Cash payments: operating cash flows 703 587 Cash payments: investing activities 90 84 With the introduction of the new R&D strategy in 2018, GSK has Contingent consideration at end of the year 5,937 5,542 revised its definition of free cash flow, a non-IFRS measure, to include proceeds from the sale of intangible assets.
This balances Of the contingent consideration payable on a post-tax basis to with the expenditure on purchases of intangible assets, which is Shionogi at 31 December 2018, 815 million 31 December deducted in calculating free cash flow, and makes the treatment 2017 724 million is expected to be paid within one year.
of intangible assets consistent with property, plant and equipment.
Free cash flow is now defined as the net cash inflow from operating Exit rights activities less capital expenditure on property, plant and equipment Pfizer may request an IPO of ViiV Healthcare at any time and if and intangible assets, contingent consideration payments, net either GSK does not consent to such IPO or an offering is not interest, and dividends paid to non-controlling interests plus completed within nine months, Pfizer could require GSK to acquire proceeds from the sale of property, plant and equipment and its shareholding.
Under the original agreements, GSK had the intangible assets, and dividends received from joint ventures and unconditional right, so long as it made no subsequent distribution to associates.
It is used by management for planning and reporting its shareholders, to withhold its consent to the exercise of the Pfizer purposes and in discussions with and presentations to investment put option and, as a result, in accordance with IFRS, GSK did not analysts and rating agencies.
Free cash flow growth is calculated on recognise a liability for the put option on its balance sheet.
A reconciliation of net cash inflow from operations during Q1 2016, GSK notified Pfizer that it had irrevocably given up to free cash flow is set out on page 56. this right and accordingly recognised the liability for the put option on the Groups balance sheet during Q1 2016 at an initial value of Free cash flow conversion 1,070 million.
Consistent with this revised treatment, at the end of Q1 2016 GSK also recognised liabilities for the future preferential Free cash flow conversion is free cash flow as a percentage of dividends anticipated to become payable to Pfizer and Shionogi on earnings.
Working capital conversion cycle The closing balances of the liabilities related to Pfizers shareholding are as follows: The working capital conversion cycle is calculated as the number of days sales outstanding plus days inventory outstanding, less days 2018 2017 purchases outstanding.
m m Pfizer put option 1,240 1,304 CER and AER growth Pfizer preferential dividend 15 17 In order to illustrate underlying performance, it is the Groups practice Under the original agreements, Shionogi could also have requested to discuss its results in terms of constant exchange rate CER GSK to acquire its shareholding in ViiV Healthcare in six month growth.
This represents growth calculated as if the exchange rates windows commencing in 2017, 2020 and 2022.
GSK had the used to determine the results of overseas companies in Sterling had unconditional right, so long as it made no subsequent distribution remained unchanged from those used in the comparative period.
to its shareholders, to withhold its consent to the exercise of the CER% represents growth at constant exchange rates.
% or AER% Shionogi put option and, as a result, GSK did not recognise a represents growth at actual exchange rates.
liability for the put option on its balance sheet.
